CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade Astellas Pharma Inc. - 4503 CFD

2076.17
2.01%
11.66
Low: 2061.11
High: 2080.26
Market Trading Hours* (UTC) Opens on Monday at 00:00

Mon - Fri: 00:00 - 02:30 03:30 - 06:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 11.66
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0221 %
Charges from borrowed part ($-0.88)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0221%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0221 %
Charges from borrowed part ($-0.88)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0224%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency JPY
Margin 20%
Stock exchange Japan
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 2118.76
Open* 2079.56
1-Year Change* 18.9%
Day's Range* 2061.11 - 2061.11
52 wk Range 1739-2205
Average Volume (10 days) 3.68349
Average Volume (3 months) 91.0081
Market Cap 3926890
P/E Ratio 26.3537
Shares Outstanding 1822610000
Revenue 1406680
EPS 81.1652
Dividend (Yield %) 2.5713
Beta 0.95006
Next Earnings Date Jan 31, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 2, 2022 2076.17 -18.45 -0.88% 2094.62 2096.12 2058.22
Dec 1, 2022 2118.76 -0.79 -0.04% 2119.55 2133.12 2108.59
Nov 30, 2022 2120.66 4.70 0.22% 2115.96 2121.35 2096.62
Nov 29, 2022 2124.15 -6.58 -0.31% 2130.73 2139.90 2112.28
Nov 28, 2022 2133.52 -4.99 -0.23% 2138.51 2147.18 2126.04
Nov 25, 2022 2139.51 -11.47 -0.53% 2150.98 2153.97 2133.02
Nov 24, 2022 2141.50 -12.47 -0.58% 2153.97 2164.74 2137.91
Nov 22, 2022 2129.43 8.87 0.42% 2120.56 2143.20 2120.06
Nov 21, 2022 2094.72 -13.57 -0.64% 2108.29 2112.08 2093.03
Nov 18, 2022 2105.59 28.52 1.37% 2077.07 2107.49 2073.68
Nov 17, 2022 2063.21 18.46 0.90% 2044.75 2067.79 2044.75
Nov 16, 2022 2056.72 -22.44 -1.08% 2079.16 2079.16 2052.23
Nov 15, 2022 2091.13 14.46 0.70% 2076.67 2102.50 2076.67
Nov 14, 2022 2039.27 -14.45 -0.70% 2053.72 2062.21 2035.28
Nov 11, 2022 2073.68 -9.96 -0.48% 2083.64 2087.64 2056.62
Nov 10, 2022 2061.71 19.45 0.95% 2042.26 2063.70 2038.87
Nov 9, 2022 2062.70 -18.95 -0.91% 2081.65 2085.15 2051.73
Nov 8, 2022 2083.85 25.14 1.22% 2058.71 2090.73 2058.71
Nov 7, 2022 2058.72 4.99 0.24% 2053.73 2061.61 2042.76
Nov 4, 2022 2063.21 6.99 0.34% 2056.22 2076.87 2044.75

Astellas Pharma Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2017 2018 2019 2020 2021 2022
Total revenue 1311660 1300320 1306350 1300840 1249530 1296160
Revenue 1311660 1300320 1306350 1300840 1249530 1296160
Cost of Revenue, Total 320503 294250 292050 276739 246063 253009
Gross Profit 991162 1006070 1014300 1024100 1003460 1043150
Total Operating Expense 1051480 1087530 1062440 1056850 1102920 1135390
Selling/General/Admin. Expenses, Total 470777 478330 490263 499295 504316 548840
Research & Development 208129 220781 208682 224226 224489 246010
Depreciation / Amortization 35837 35838 35212 21164 23763 28283
Interest Expense (Income) - Net Operating -5082 12887 892 10588 1854 -8661
Unusual Expense (Income) 18707 52023 43425 12903 102469 66036
Other Operating Expenses, Total 2606 -6577 -8088 11937 -35 1876
Operating Income 260188 212784 243912 243991 146609 160770
Interest Income (Expense), Net Non-Operating 21541 5315 1468 16 -1358 -1454
Other, Net 40 14 3587 1343 73 -2430
Net Income Before Taxes 281769 218113 248967 245350 145324 156886
Net Income After Taxes 218700 164679 222265 195411 120590 124086
Net Income Before Extra. Items 218700 164679 222265 195411 120590 124086
Net Income 218700 164679 222265 195411 120590 124086
Total Adjustments to Net Income 1 -1
Income Available to Common Excl. Extra. Items 218701 164679 222265 195411 120589 124086
Income Available to Common Incl. Extra. Items 218701 164679 222265 195411 120589 124086
Diluted Net Income 218701 164679 222265 195411 120589 124086
Diluted Weighted Average Shares 2111.98 2032.47 1933.74 1877.55 1857.12 1850.6
Diluted EPS Excluding Extraordinary Items 103.553 81.024 114.94 104.078 64.9332 67.0517
Dividends per Share - Common Stock Primary Issue 34 36 38 40 42 50
Diluted Normalized EPS 110.428 100.349 134.988 109.551 110.718 95.2749
Q4 2021 Q1 2021 Q2 2021 Q3 2021 Q4 2022
Total revenue 308621 326143 325523 340627 303870
Revenue 308621 326143 325523 340627 303870
Cost of Revenue, Total 58327 62231 62504 69359 58915
Gross Profit 250294 263912 263019 271268 244955
Total Operating Expense 332040 290053 271445 261425 317555
Selling/General/Admin. Expenses, Total 141272 137109 133397 135914 142420
Research & Development 55668 58313 60747 58588 68362
Depreciation / Amortization 6469 5963 6416 7868 8036
Interest Expense (Income) - Net Operating -744 -292 -16 -1724 1543
Other Operating Expenses, Total 71048 677 8395 -3072 -5512
Operating Income -23419 36090 54078 79202 -13685
Interest Income (Expense), Net Non-Operating 4515 -260 -823 -885 3168
Other, Net 1 1
Net Income Before Taxes -18903 35830 53255 78317 -10516
Net Income After Taxes -12327 30686 40922 60886 -8408
Net Income Before Extra. Items -12327 30686 40922 60886 -8408
Net Income -12327 30686 40922 60886 -8408
Total Adjustments to Net Income -1 1 -1 -1
Income Available to Common Excl. Extra. Items -12328 30687 40922 60885 -8409
Income Available to Common Incl. Extra. Items -12328 30687 40922 60885 -8409
Diluted Net Income -12328 30687 40922 60885 -8409
Diluted Weighted Average Shares 1856.05 1853.78 1853.78 1852.91 1840.23
Diluted EPS Excluding Extraordinary Items -6.64208 16.5537 22.0749 32.8592 -4.56954
Dividends per Share - Common Stock Primary Issue 21 0 25 0 25
Diluted Normalized EPS -6.64208 28.5896 22.0758 30.5481 10.8982
Unusual Expense (Income) 26052 2 -5508 43791
  • Annual
  • Quarterly
2017 2018 2019 2020 2021 2022
Total Current Assets 876665 845619 857159 867514 872588 923354
Cash and Short Term Investments 340923 331731 311074 324943 326128 318267
Cash & Equivalents 331801 328669 297477 313126 326128 315986
Short Term Investments 9122 3062 13597 11817 2281
Total Receivables, Net 334357 341441 365348 373505 362722 423018
Accounts Receivable - Trade, Net 309817 319512 342628 347042 343178 382462
Total Inventory 182537 147626 151511 151017 164080 153072
Prepaid Expenses 10763 9149 12743
Other Current Assets, Total 8085 15672 16483 18049 19658 28997
Total Assets 1814070 1858200 1897650 2315170 2273630 2332400
Property/Plant/Equipment, Total - Net 191115 181295 173483 268600 264623 269044
Property/Plant/Equipment, Total - Gross 469188 464709 448245 564186 592329 624055
Accumulated Depreciation, Total -278073 -283414 -274762 -295586 -327707 -355010
Goodwill, Net 168521 212976 225864 278253 284011 303030
Intangibles, Net 387419 416912 429707 724773 651427 623431
Long Term Investments 54178 59780 75462 66399 91704 91009
Note Receivable - Long Term 32684 36027 34912 46570 45188 40666
Other Long Term Assets, Total 103490 105596 101061 63060 64087 81861
Total Current Liabilities 399856 421620 497665 798708 592372 687411
Accounts Payable 182826 140909 185280 171954 124777 130739
Notes Payable/Short Term Debt 0 0 0 326000 120000 140000
Current Port. of LT Debt/Capital Leases 499 444 430 18105 16101 17730
Other Current Liabilities, Total 216531 280267 311955 282649 331494 398942
Total Liabilities 542262 589916 639252 1026000 887513 872087
Total Long Term Debt 28389 49422 52882 129272 142163 55014
Long Term Debt 27253 48518 52113 60045 80000 0
Capital Lease Obligations 1136 904 769 69227 62163 55014
Deferred Income Tax 18514 26426 5175 24670 18161 5823
Other Liabilities, Total 95503 92448 83530 73351 134817 123839
Total Equity 1271810 1268290 1258400 1289170 1386120 1460310
Common Stock 103001 103001 103001 103001 103001 103001
Additional Paid-In Capital 177091 177219 177301 177506 177830 179467
Retained Earnings (Accumulated Deficit) 1015710 977553 993084 906750 954034 944891
Treasury Stock - Common -138207 -135951 -164629 -7178 -15377 -13934
Unrealized Gain (Loss) 14629 18289
Other Equity, Total 99589 128178 149639 109089 166627 246883
Total Liabilities & Shareholders’ Equity 1814070 1858200 1897650 2315170 2273630 2332400
Total Common Shares Outstanding 2065.01 1976.15 1885.84 1857.51 1853.03 1827.07
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 872588 868715 876454 939331 923354
Cash and Short Term Investments 326128 305995 328288 368093 318266
Cash & Equivalents 326128 301920 318295 350213 315986
Total Receivables, Net 362722 381528 375370 390722 423018
Accounts Receivable - Trade, Net 343178 364233 357801 373923 382462
Total Inventory 164080 157254 148732 151576 153072
Other Current Assets, Total 19658 23938 24064 28940 28998
Total Assets 2273630 2249460 2261510 2356240 2332400
Property/Plant/Equipment, Total - Net 264623 269698 266671 267817 269044
Property/Plant/Equipment, Total - Gross 592329 624055
Accumulated Depreciation, Total -327707 -355010
Goodwill, Net 284011 284114 284993 293649 303030
Intangibles, Net 651427 630322 640981 652251 623431
Long Term Investments 91704 99570 95674 104306 91009
Note Receivable - Long Term 45188 32829 32376 30365 40666
Other Long Term Assets, Total 64087 64208 64359 68526 81861
Total Current Liabilities 592372 581580 554768 597976 687411
Accounts Payable 124777 108453 111568 136892 130739
Notes Payable/Short Term Debt 120000 0 0 0 140000
Current Port. of LT Debt/Capital Leases 16101 147493 106117 108710 17730
Other Current Liabilities, Total 331494 325634 337083 352374 398942
Total Liabilities 887513 866587 843886 889954 872087
Total Long Term Debt 142163 201362 204838 201534 55014
Long Term Debt 80000 201362 204838 201534 0
Capital Lease Obligations 62163 55014
Deferred Income Tax 18161 8175 9371 10618 5823
Other Liabilities, Total 134817 75470 74909 79826 123839
Total Equity 1386120 1382870 1417620 1466290 1460310
Common Stock 103001 103001 103001 103001 103001
Additional Paid-In Capital 177830 177657 178531 179042 179467
Retained Earnings (Accumulated Deficit) 954034 946678 985932 999640 944891
Treasury Stock - Common -15377 -15663 -15605 -15520 -13934
Other Equity, Total 166627 171196 165763 200128 246883
Total Liabilities & Shareholders’ Equity 2273630 2249460 2261510 2356240 2332400
Total Common Shares Outstanding 1853.03 1852.85 1852.88 1852.93 1827.07
Short Term Investments 4075 9993 17880 2280
  • Annual
  • Quarterly
2017 2018 2019 2020 2021 2022
Net income/Starting Line 281769 218113 248967 245350 145324 156886
Cash From Operating Activities 235612 312615 256899 221997 306843 257443
Cash From Operating Activities 63791 64863 63458 66396 72652 79684
Non-Cash Items -4600 37544 6391 12437 91075 73650
Cash Taxes Paid 72004 65021 69913 47993 17870 42093
Changes in Working Capital -105348 -7905 -61917 -102186 -2208 -52777
Cash From Investing Activities -73383 -121799 -41757 -389793 -81894 -62413
Capital Expenditures -48648 -40285 -52128 -77888 -77441 -76448
Other Investing Cash Flow Items, Total -24735 -81514 10371 -311905 -4453 14035
Cash From Financing Activities -166153 -203429 -233681 181055 -229479 -216298
Financing Cash Flow Items -3841 -1083 -1173 -847 -2268 -2530
Total Cash Dividends Paid -70119 -71634 -72066 -73539 -76157 -85236
Issuance (Retirement) of Stock, Net -92193 -130712 -160442 -52899 -9163 -50717
Foreign Exchange Effects -15183 3421 -2118 -5942 12267 11125
Net Change in Cash -19107 -9192 -20657 7317 7737 -10143
Issuance (Retirement) of Debt, Net 308340 -141891 -77815
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line 145324 35830 89085 167402 156886
Cash From Operating Activities 306843 40083 139385 208859 257443
Cash From Operating Activities 72652 18144 37081 58602 79684
Non-Cash Items 91075 26312 27137 28686 73650
Cash Taxes Paid 17870 10251 24066 33834 42093
Changes in Working Capital -2208 -40203 -13918 -45831 -52777
Cash From Investing Activities -81894 -21085 -55744 -47586 -62413
Capital Expenditures -77441 -19912 -47875 -59176 -76448
Other Investing Cash Flow Items, Total -4453 -1173 -7869 11590 14035
Cash From Financing Activities -229479 -44730 -89936 -141264 -216298
Financing Cash Flow Items -2268 -634 -1224 -1840 -2530
Total Cash Dividends Paid -76157 -38914 -38914 -85236 -85236
Issuance (Retirement) of Stock, Net -9163 -713 -715 -716 -50717
Issuance (Retirement) of Debt, Net -141891 -4469 -49083 -53472 -77815
Foreign Exchange Effects 12267 1524 -1539 4076 11125
Net Change in Cash 7737 -24208 -7834 24085 -10143

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
475000+

Traders

71000+

Active clients monthly

$51000000+

Monthly investing volume

$30000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Astellas Pharma Inc. Company profile

About Astellas Pharma Inc

Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.

Financial summary

BRIEF: For the nine months ended 31 December 2021, Astellas Pharma Inc revenues increased 5% to Y992.29B. Net income applicable to common stockholders decreased less than 1% to Y132.49B. Revenues reflect Sales of Pharmaceuticals segment increase of 6% to Y971.11B, Other Business segment increase of 33% to Y14.07B, Americas segment increase of 15% to Y407.94B, Estabridge segment increase of 10% to Y239.22B.

Equity composition

04/2005, Company merged with Fujisawa Pharmaceutical Co., Ltd. & Name Changed from Yamanouchi Pharmaceutical Co., Ltd. FY'08 1Q&Q3 WAS & DWAS estimated and WAS used as O/S. FY'09 Q3,12 Q2 DWAS estimated.

Industry: Pharmaceuticals (NEC)

日本橋本町2-5-1
103-8411

Income Statement

People also watch

US100

11,963.60 Price
-0.470% 1D Chg, %
Long position overnight fee -0.0166%
Short position overnight fee 0.0060%
Overnight fee time 22:00 (UTC)
Spread 3.3

BTC/USD

17,145.65 Price
+0.920% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 66.00

Oil - Crude

80.34 Price
-1.310% 1D Chg, %
Long position overnight fee -0.0024%
Short position overnight fee -0.0116%
Overnight fee time 22:00 (UTC)
Spread 0.03

Natural Gas

6.21 Price
-8.960% 1D Chg, %
Long position overnight fee 0.0408%
Short position overnight fee -0.0658%
Overnight fee time 22:00 (UTC)
Spread 0.005

Still looking for a broker you can trust?

Join the 475.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading